ArticleFrontiers in pharmacology2026
Knowledge graph and machine learning-guided virtual screening prioritizes putative blockers of the PSMD11/Rpn6-EBOV glycoprotein interface.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Host-directed antiviral discovery requires a traceable route from host-factor identification to testable molecular hypotheses. This study developed such a workflow around a host factor associated with Ebola virus glycoprotein (EBOV GP). Methods: GFP-GP pulldown coupled with co-immunoprecipitation/mass spectrometry was used to identify GP-associated host candidates. A PSMD11/Rpn6-centred workflow integrated knowledge-graph inference, ligand-only machine learning, ADMETlab profiling and interface-guided docking. Candidate prioritization was assessed through score-weight sensitivity analysis, applicability-domain assessment and docking controls addressing seed reproducibility, search convergence, whole-receptor context and macrocycle ring-conformer sensitivity. Docking scores were contextualized against a matched 59-compound library. Results: The analysis recovered 424 GP-pulldown-specific host proteins and nominated PSMD11/Rpn6 as a proteostasis anchor. The tier-gated knowledge-graph candidate membership was invariant across the tested weight perturbations, with Spearman rho = 0.998 under equal weighting. The selected ExtraTrees model achieved an AUC of 0.912 for the Ki endpoint. Applicability-domain assessment and ADMET profiling differentiated candidate confidence and predicted liabilities. Docking reproducibility checks yielded a maximum standard deviation of 0.05 kcal/mol for conformationally restricted ligands, while macrocyclic candidates showed greater protocol-dependent variability. Rule-based triage integrating upstream evidence, ADMET burden, chemotype diversity and mechanistic coverage returned five candidates: betamethasone, bafilomycin A1, everolimus, pitavastatin and CHEMBL1410015. Discussion: The workflow links a proteomic host-factor signal to a compact set of chemically diverse hypotheses with explicit evidence sources and limitations. The candidates remain hypotheses for experimental assessment; direct target engagement, interface blockade and antiviral activity are not established by the present study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.